Core Viewpoint - Dachen Biochemical Technology (00809) reported a revenue of HKD 2.279 billion for the year ending December 31, 2025, reflecting a year-on-year increase of 13.86%. However, net profit decreased by 79.69% to HKD 156 million, with basic earnings per share at HKD 0.014 [2]. Group 1: Financial Performance - The company achieved a revenue of HKD 2.279 billion, which is a 13.86% increase compared to the previous year [2]. - The net profit for the year was HKD 156 million, representing a significant decrease of 79.69% year-on-year [2]. - Basic earnings per share were reported at HKD 0.014 [2]. Group 2: Market Conditions and Production - The company maximized production capacity for its amino acid business, resulting in a sales volume increase of approximately 36.6% to 522,000 metric tons, compared to 382,000 metric tons in 2024 [2]. - Due to intense domestic market competition, local suppliers are shifting to sell amino acid products in the domestic market [2]. - Starting from the second half of 2025, the EU and the US will impose final anti-dumping duties on China's lysine products, leading the company to adjust its amino acid production in the fourth quarter of 2025 to achieve optimal production rates [2].